Elsevier

Clinica Chimica Acta

Volume 404, Issue 2, 27 June 2009, Pages 100-104
Clinica Chimica Acta

Optimizing the yield and utility of circulating cell-free DNA from plasma and serum

https://doi.org/10.1016/j.cca.2009.02.018Get rights and content

Abstract

Background

Cell-free DNA (CFDNA) in the plasma/serum of patients with cancer demonstrates tumour-associated genetic alterations, offering possibilities for diagnosis, prognostication and disease monitoring. There is wide variation in the reported levels of CFDNA, associated with different methods used to collect, process and analyze blood samples. We therefore evaluated different aspects of laboratory protocols for the processing and purification of CFDNA in clinical studies.

Methods

We evaluated and compared the QIAamp kit and a Triton/Heat/Phenol protocol (THP) for CFDNA purification. Total CFDNA was quantified by PicoGreen assay and SYBR-Green real-time PCR assay was used to amplify specific genes to estimate the efficiency of different protocols.

Results

The efficiency of DNA extraction was 18.6% using the standard QIAamp protocol and 38.7% using the THP method (p < 0.0001, unpaired t-test). A modified QIAamp protocol that included a proteinase incubation stage and elution volumes up to 300 μl increased DNA yields, but was not as good as the THP method.

Conclusions

Blood samples should be kept at/or below room temperature (18 °C–22 °C) for no more than 2 h before plasma separation by double-spin. Because of its higher efficiency, low-cost and good-quality products, the THP protocol is preferred for extraction of CFDNA.

Introduction

Cell-free circulating DNA (CFDNA) has been studied in a wide range of physiological and pathological conditions, including pregnancy, trauma, inflammatory disorders and malignancy [1], [2]. It is present in normal healthy individuals at low concentrations (ng/ml) [3]. Raised levels of CFDNA in cancer patients have been reported in many tumour types [2], [3], [4], [5]. The finding that genetic and epigenetic changes typical of tumours can be detected in CFDNA from cancer patients, suggests that the excess CFDNA is of tumour origin. Although the precise mechanism of DNA release into the blood remains uncertain, it probably derives from a combination of apoptosis, necrosis and active release from tumour cells [6]. Such cell-free DNA has shown promise for improving early clinical diagnosis, prognostication and disease monitoring in inaccessible tumour types, such as lung cancer [7], [8], [9], [10], [11].

Although higher levels of CFDNA are consistently reported in cancer patients than healthy controls, there is considerable variation between studies. This may be attributable to differences in study design including selection of patient and control groups, and the methods used to extract and quantify CFDNA [10], [12], [13], [14]. No agreed standards exist, and many publications fail to specify how samples were obtained, processed and analyzed. The problems of prolonged sample storage have been highlighted by a recent report that DNA levels in plasma stored at − 80 °C declined by 30% per year [15]. Thus, this study was designed to evaluate the factors most likely to influence the yield of CFDNA from clinical samples.

Various methods have been used to purify CFDNA, including using modified salting-out [16], chromatography resins [16], [17], magnetic beads [18], or guanidium thiocyanate [19]. The most popular is the QIAamp blood kit, which binds DNA to a silica-gel membrane, providing a fast and easy way to purify total DNA for polymerase chain reaction (PCR) analysis. We found that the recovery of CFDNA was less than 20% using the QIAamp DNA Midi Kit. Some authors have recommended using a predigestive buffer in plasma/serum samples to improve the results [16], [18], [20]. Therefore, we have evaluated standard and modified QIAamp protocols and compared them with a simple Triton/Heat/Phenol (THP) protocol. Because DNA is present in plasma/serum at such low concentrations (ng/ml), it is crucial to optimize laboratory protocols for the processing and extraction of CFDNA.

Section snippets

Sample collection and preparation

To compare different CFDNA extraction protocols, commercial pooled human serum (SLI Ltd, UK) was spiked with reference genomic DNA (Sigma-Aldrich, UK) or a known amount of linearized bcl-2 plasmid reference DNA (final concentration in serum: 0, 50 and 100 ng/ml). For clinical samples, 20 ml peripheral blood was collected from healthy volunteers into EDTA tubes [21]. Plasma was separated by double centrifugation (800 g for 10 min, separation, and 1600 g for 10 min). Plasma aliquots were

Optimization of QIAamp protocol

Digesting or denaturing the plasma/serum proteins is one of the most important stages during the extraction of CFDNA. We compared the protease provided in the QIAamp Blood Kit with proteinase K for the purification of low quantities of CFDNA. Fig. 1 shows that pre-incubation of serum samples with proteinase K (400 μg/ml) at 37 °C for 1 h (Q37-1, P37-1) significantly increased the DNA recovery compared to no incubation (QN, PN) (QN vs Q37-1: p = 0.003; PN vs P37-1: p = 0.002) and there was

Discussion

Published studies on CFDNA in cancer patients give remarkably little detail about the conditions under which clinical samples were obtained, transported, stored or processed, making comparisons of the reported results difficult. Very few studies have addressed the efficiency or reproducibility of their chosen DNA extraction methods. We were initially surprised to obtain DNA yields of less than 20%, but a detailed literature review showed that this was not unusual [16], [17]. There is clearly a

References (28)

  • O. Gautschi et al.

    Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy

    J Clin Oncol

    (2004)
  • X. Xue et al.

    Circulating DNA and lung cancer

    Ann N Y Acad Sci

    (2006)
  • S. Khan et al.

    Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases

    Int J Cancer

    (2004)
  • J.L. Boddy et al.

    Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease

    Clin Cancer Res

    (2005)
  • Cited by (129)

    • A modular and reconfigurable open-channel gated device for the electrokinetic extraction of cell-free DNA assays

      2022, Analytica Chimica Acta
      Citation Excerpt :

      These effects were explored as a result of, for example, the suggestion by Sullivan et al. [26] that short incubation times with high doses of proteinase K were sufficient for the successful separation of small DNA from plasma samples using tITP. Note that previous studies on cfDNA extraction from plasma have used about 500 μg/ml of proteinase K (e.g. Ref. [16], used 400 μg/ml). In the present study, it is hypothesized that the effects of the proteinase K concentration on the plasma samples result from the creation of a fraction of a high-mobility peptide species.

    • False Positives in Brucellosis Serology: Wrong Bait and Wrong Pond?

      2023, Tropical Medicine and Infectious Disease
    View all citing articles on Scopus
    View full text